Literature DB >> 170211

Vaccination against feline leukaemia virus using a cell membrane antigen system.

W Jarrett, O Jarrett, L Mackey, H Laird, C Hood, D Hay.   

Abstract

Cats inoculated with live feline lymphoblastoid cells of the FL74 line developed high titres of antibody to feline oncornavirus-associated cell membrane antigen (FOCMA). Eight cats were subsequently challenged with a large dose of feline leukaemia virus (FeLV) of a highly pathogenic strain. All resisted infection while 10 cats given the challenge virus alone became infected. The FeLV produced by FL74 cells was shown to be of extremely low infectivity in cats and in cultured feline cells. Cats inoculated with either FL74 cells or virus purified from them did not become infected. The purified virus did not induce FOCMA antibody in cats not previously exposed to FeLV. The fact that FL74 cells are highly immunogenic, but produce virus of low infectivity, is of value in devising vaccines against FeLV. Cats were also inoculated with FL74 cells which had been inactivated with paraformaldehyde. They developed FOCMA antibody, reaching a peak titre of 256, and no virus could be cultured either from the vaccine preparations or from the tissues of the cats.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170211     DOI: 10.1002/ijc.2910160115

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.

Authors:  R G Olsen; M G Lewis; L J Lafrado; L E Mathes; K Haffer; R Sharpee
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Pseudotypes of feline sarcoma virus contain an 85,000-dalton protein with feline oncornavirus-associated cell membrane antigen (FOCMA) activity.

Authors:  C J Sherr; A Sen; G J Todaro; A Sliski; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

Review 3.  Leukaemia 'firsts' in cancer research and treatment.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

4.  Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective.

Authors:  N C Pedersen; L Johnson; D Birch; G H Theilen
Journal:  Vet Immunol Immunopathol       Date:  1986-02       Impact factor: 2.046

5.  Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated.

Authors:  E A Hoover; J P Schaller; L E Mathes; R G Olsen
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

6.  Immune response and resistance to Rous sarcoma virus challenge of chickens immunized with cell-associated glycoproteins provided with a recombinant avian leukosis virus.

Authors:  Y Chebloune; J Rulka; F L Cosset; S Valsesia; C Ronfort; C Legras; A Drynda; J Kuzmak; V M Nigon; G Verdier
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Protection against feline leukemia by vaccination with a subunit vaccine.

Authors:  M G Lewis; L E Mathes; R G Olsen
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma.

Authors:  G Hunsmann; N C Pedersen; G H Theilen; H Bayer
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

9.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas.

Authors:  L E Posner; M Robert-Guroff; V S Kalyanaraman; B J Poiesz; F W Ruscetti; B Fossieck; P A Bunn; J D Minna; R C Gallo
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.